key: cord-0718691-8tcphv8g
authors: Lanza, Gaetano A.
title: Autonomic dysfunction and post-COVID-19 syndrome: a still elusive link
date: 2021-12-28
journal: Heart Rhythm
DOI: 10.1016/j.hrthm.2021.12.027
sha: cbf7738ee8e0d79af4ce2dfebf866e13383643c3
doc_id: 718691
cord_uid: 8tcphv8g

nan

Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a long-lasting pandemia, the coronavirus disease 2019 (COVID-19), with dramatic clinical, social and economic implications. Importantly, evolving experience consistently shows that, besides the issues related to the acute phase, patients who recover from COVID-19 may present a wide variety of bothersome symptoms, which may be debilitating and significantly impair their quality of life, a condition that when persisting beyond 12 weeks after recovery is defined "post-COVID-19" or "long-COVID-19" syndrome (1) .

Several of these symptoms, including tachycardia/palpitations, chest pain, fatigue and dyspnea with reduced effort tolerance, suggest a possible cardiovascular cause, while others (e.g., muscle and/or joint pain, headache, memory loss, nausea, mood disturbances) suggest involvement of other systems. Symptoms may occur independently of the severity of COVID-19, although patients with more severe symptoms in the acute phase experience a higher rate of symptoms' persistence during follow-up (1,2). Importantly, careful diagnostic assessment usually fails to identify specific causes of post-COVID-19 syndrome. It has been suggested, however, that at least a number of post-COVI-19 symptoms, including those of potential cardiovascular origin, might be related to abnormalities of the autonomic nervous system (ANS) (3). The pathophysiologic mechanisms responsible for ANS impairment, however, remain speculative and might include a direct damage of the ANS (ganglia and/or nerve terminations) by the virus, a toxic effect of inflammatory cytokines released during the acute infection and an immune-mediated response triggered by some viral component(s) (1, 3) . Independently of the mechanism, the possibility of ANS involvement in SARS-J o u r n a l P r e -p r o o f CoV2 infection is supported by the frequent occurrence of neurologic symptoms (e.g., anosmia, dysgeusia) as well as the sporadic occurrence of clinical conditions typically related to ANS dysfunction (e.g., orthostatic hypotension, orthostatic tachycardia) in the post-COVID-19 syndrome (3) . Furthermore, patients with COVID-19, as compared to healthy subjects, have been found to show reduced heart rate variability (HRV) parameters after 20 weeks from recovery from the illness (4). However, a pathogenetic relation between dysautonomia and post-COVID-syndrome remains still to be demonstrated. Yet, establishing such a relation would be of obvious importance, since it might help guide the management of this clinical condition.

The study by Ladlow et al. published in this number of the Journal is therefore welcome as it tries to clarify whether any association exists between dysautonomia and symptoms, as well as objective evidence of exercise intolerance, in patients with post-COVID-19 syndrome (5) . In this study the authors enrolled 205 patients referred to their post-COVID-19 clinic who fulfilled specific eligibility criteria (hospitalization and desaturation ≤95% on a Harvard step test or chest pain with ECG changes during acute illness and life limiting symptoms persisting for >12 weeks). All patients underwent a bicycle cardiopulmonary exercise testing (CPET) and were divided in 2 groups, according to the evidence or not of dysautonomia.

Dysautonomia was diagnosed based on 3 heart rate (HR) parameters that Jouven et al.

found to be associated with total mortality and sudden death in a population of asymptomatic subjects: 1) a resting HR >75 bpm; 2) an increase in HR during exercise <89 bpm; and 3) an HR reduction <25 bpm during the first minute of recovery from peak exercise (6) . HRV was also assessed by calculating the root mean square of the J o u r n a l P r e -p r o o f squared differences of adjacent RR intervals (RMSSD) on a 1-minute 12-lead electrocardiogram (ECG) at rest and on 30-second ECGs during the first 3 minutes of recovery after peak exercise.

Patients were studied 183±77 days (~6-months) from COVID-19 disease and dysautonomia was found in 51 patients (25%). As per definition, these patients had higher HR at rest (95±12 vs. 81±12 bpm, p<0.001) and lower HR increase during CPET (75±12 vs. 96±13 bpm, p<0.001) and HR recovery after peak exercise (17±4 vs. 31±17 bpm, p<0.001), compared to those without dysautonomia.

Patients with dysautonomia were older, had a higher body mass index (BMI, p=0.013) and waist circumference (WC, p=0.003), and a lower basal RMSSD (p<0.001).

Furthermore, at rest dysautonomic patients showed a higher breathing rate (p=0.006) and lower forced vital capacity (p=0.031), forced expiratory volume in 1 second (p=0.036) and ventilatory efficiency (VE/VCO2; p=0.036).

When assessing symptoms that showed a prevalence >25%, a significant association with dysautonomia was found for low mood (p=0.007), headache (p=0.026) and poor attention (p=0.047). However, other symptoms, including some of those of potential cardiovascular origin (shortness of breath, fatigue), showed no significant association with dysautonomia.

Patients with dysautonomia, however, showed a lower performance on CPET.

Particularly, HR at peak exercise (170±13 vs. 177±15 bpm, p=0.003), maximal work rate (219±37 vs. 253±52 W; p<0.001) and maximal oxygen consumption (V O2) While the study shows the lack of significant relation between dysautonomia and most post-COVID-19 symptoms, including, particularly, some symptoms of possible cardiovascular origin, it should be recognized that the method applied to identify patients with an impairment of ANS function presents some limitations. Both a higher HR at rest and a lower HR recovery after exercise suggest, indeed, an imbalance of sympatho-vagal tone towards adrenergic predominance in their patients with dysautonomia; however, rather than reflecting a primary impairment of the ANS, these findings might have simply been related to differences between the 2 groups in some basal clinical characteristics, including a higher BMI/WC, a lower efficiency in respiratory function, and also a lower mood in dysautonomic patients. On the other hand, the lower increase in HR during maximal exercise in patients with dysautonomia might have been a mere consequence of the fact that they had a higher HR at rest and, given their older age, had also a lower maximal theoretic HR for age. The percent of the predicted maximal HR for age achieved during CPET, in fact, did not differ between the Future studies should, therefore, clarify if different results on the relation between ANS dysfunction and post-COVID-19 symptoms might be obtained using more comprehensive and better validated methods for the diagnosis of ANS dysfunction, such as standard tests of autonomic function (7) and HRV assessed in its multiple, short-term and long-term, components (8) .

Of note, while the results of CPT in the Ladlow study suggest a lower performance in patients classified with dysautonomia (5), it should be observed that exercise tolerance was largely normal in these subjects, who achieved more than 100% of the predicted maximal oxygen consumption and an average maximal work rate of 219 W, with only small differences compared to patients without dysautonomia, possibly explained, again, and at least in part, by some demographic (age) and clinical (BMI, respiratory function) differences.

In conclusion, the study by Ladlow et al. (5) provides interesting data on the clinical characteristics and objective physical performance of patients with post-COVID-19 syndrome. On the other hand, the role of ANS in determining symptoms (particularly those of potential cardiovascular origin) and physical limitation in these patients remains not fully elucidated by their data, making necessary further studies applying more comprehensive and valuable methods for the assessment of ANS function.

J o u r n a l P r e -p r o o f

Post-acute COVID-19 syndrome

Post-COVID syndrome in non-hospitalized patients with COVId-19; a longitudinal prospective cohort study

Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies

Altered cardiac autonomic function after recovery from COVID-19

Dysautonomia following COVID-1 19 is not associated with subjective limitations or symptoms, but is associated with objective functional limitation

Heart-rate profile during exercise as a predictor of sudden death

Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology

Heart rate variability: measurement and clinical utility